Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03882970 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,444
- Enrollment target
NCT03882970: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT03882970 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,444 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03882970, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,444 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
Primary Outcome
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Interventions
- DRUG Tirzepatide
- DRUG Insulin Degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,444 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-01-04 |
| Phase | Phase 3 |
What the finished NCT03882970 record still lists
NCT03882970 is an interventional study that assigns participants to a tested intervention. Its 1,444 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT03882970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03882970 about?
NCT03882970 is a clinical study titled "A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes". The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
What is the current status of trial NCT03882970?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,444 participants. The study started on 2019-04-01. Estimated completion is 2021-01-04.
What interventions are being tested in trial NCT03882970?
The interventions under investigation include: Tirzepatide (DRUG), Insulin Degludec (DRUG).
Who is sponsoring clinical trial NCT03882970?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03882970's enrollment target sits among peer trials
1,444 167th of 2000 higher than 1,834 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI